Insider Transactions in Q1 2025 at Nurix Therapeutics, Inc. (NRIX)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 31
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,760
-7.54%
|
$115,200
$20.21 P/Share
|
|
Jan 31
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,760
+6.65%
|
$5,760
$1.86 P/Share
|
|
Jan 30
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,220
-4.54%
|
$64,400
$20.07 P/Share
|
|
Jan 30
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,674
+7.13%
|
-
|
|
Jan 30
2025
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,690
-3.11%
|
$73,800
$20.07 P/Share
|
|
Jan 30
2025
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,957
+5.0%
|
-
|
|
Jan 30
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,811
-3.34%
|
$56,220
$20.07 P/Share
|
|
Jan 30
2025
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+6.79%
|
-
|
|
Jan 02
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,760
-17.02%
|
$109,440
$19.5 P/Share
|
|
Jan 02
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,760
+14.54%
|
$5,760
$1.86 P/Share
|